Storax

Storax (Liquidambar Balsam): A Comprehensive Reference

1. Identity, Nomenclature, and Botanical Source

1.1 Names and Taxonomy

Storax — from the Latin storax and Greek στύραξ (stúrax), often commercially sold under the name styrax — is a natural fragrant resin isolated from the wounded bark of Liquidambar orientalis Mill. (Asia Minor) and Liquidambar styraciflua L. (Eastern US, Mexico, Central America), both belonging to the family Altingiaceae. It is distinct from benzoin (also commonly called "storax"), a similar resin obtained from the Styracaceae plant family.

The substance carries multiple synonyms across pharmacopoeial, commercial, and traditional systems. Storax — also named Styrax or Su-Hexiang — is a processed and refined aromatic resin exuded from the trunk of Liquidambar orientalis Mill. in the family Hamamelidaceae, as recorded in the State Pharmacopoeia Committee (2020). Other historical names include Styrax liquidus, Balsam Styracis, Liquid Storax, and Flussiger Amber.

Two principal species contribute to commercial and medicinal supply:

• Liquidambar orientalis Mill. — Commonly called the Anatolian sweetgum or Sığla tree, endemic to southwestern Turkey. The species is found only in southwestern Turkey and on the island of Rhodes. It is an endangered relict species.
• Liquidambar styraciflua L. — The American sweetgum, native to the eastern United States, Mexico, and Central America. Liquidambar styraciflua L. is an aromatic species, popularly used in traditional Chinese medicine to treat diarrhea, dysentery, coughs, and skin sores.

1.2 Morphology and Balsam Collection

These deciduous trees can reach heights of up to 30 meters, featuring scaly bark, palmately lobed leaves, and spherical fruit clusters, with the balsam collected by incising the trunk to allow the viscous liquid to ooze out before it hardens.

The bark is usually struck or broken in early summer to reach the wood so that the resin is secreted and seeped into the bark. In autumn, the injured bark is peeled off and used to extract the resin. The remaining residue is boiled in water and pressed again, then filtering out the impurities and extracting the balsam as ordinary storax. The balsam is dissolved in ethanol, filtered and steamed out of the ethanol — then it becomes refined balsam, also known as storax oil or flowing storax, characterized as semi-fluid, brown or dark brown, translucent, viscous, and aromatic.

Crude storax is a gray, thick liquid with a pleasant odor but a bitter taste. About 85% of the crude material is alcohol-soluble. Purified storax forms a brown, semisolid mass that is completely soluble in alcohol.

1.3 Common Forms and Preparations

Storax is available and used in several distinct preparations:

• Crude liquid storax (Styrax liquidus): Obtained by scoring the outer tree bark, then boiling the inner bark in water, and then pressing the inner bark in cold water.
• Purified storax: Dissolved in alcohol, filtered, and processed to prevent loss of volatile constituents, per the United States Pharmacopoeia.
• Resinoid, essential oil, and absolute: Used as flavors and fragrances, as well as in pharmaceuticals such as Friar's Balsam.
• Topical preparations: Combined with excipients such as tallow or lard for dermal application, or incorporated into ointments and tinctures.
• Traditional Chinese medicine (TCM) compounds: Due to its beneficial effects on various diseases, storax is used as a crucial ingredient in the preparation of various traditional Chinese prescriptions, for example, Guanxin Suhe Pill, Shexiang Baoxin Pill, Su Bing Dripping Pill, and Storax Pill.

2. Chemical Composition

2.1 Major Constituents of Purified Balsam

Purified storax contains about 33–50% storesin (an alcoholic resin), 5–15% cinnamic acid, 5–15% cinnamyl cinnamate, about 10% phenylpropyl cinnamate, as well as small amounts of ethyl cinnamate, benzyl cinnamate, and styrene. Some may contain traces of vanillin or triterpenic acids (oleanolic and 3-epioleanolic acids).

Storax is high in free and combined cinnamic acid, styracin, cinnamate, and volatile oils.

2.2 Volatile (Essential Oil) Fraction

Many components of the essential oil of L. orientalis have been characterized, but the major ones were terpinen-4-ol, α-terpinol, sabinene, and γ-terpinene.

One study on the gum specifically reported the primary chemical constituent as styrene, accounting for 78.5%. This proportion refers to the specific oil fraction analyzed in that study and differs from the bulk balsam composition. The volatile chemistry of storax varies by botanical source, variety, and method of extraction.

2.3 Terpenoids and Phenolic Acids

The 2021 Frontiers in Pharmacology review catalogued the terpenoid fraction comprehensively. Identified terpenoid classes include monoterpenoids, sesquiterpenoids, diterpenoids, and pentacyclic triterpenoids. Among the triterpene acids identified were oleanolic acid, oleanonic acid, betulinic acid, corosolic acid, and maslinic acid.

The major phenolic acid in storax balsam by chromatographic analysis has been identified as p-coumaric acid.

2.4 Pharmacopoeial Standards

Pharmacopoeial standards for storax balsam are outlined in the United States Pharmacopeia (USP) and British Pharmacopoeia (BP) monographs, which specify tests for identity, purity, and composition, including a minimum content of cinnamic acid derivatives determined by saponification and titration methods. These standards require that purified storax yields not less than a specified amount of cinnamic acid upon hydrolysis, typically aligning with 33–50% ester content to ensure quality for medicinal and pharmaceutical applications. Both the British Pharmacopoeia and the German Pharmacopoeia direct that storax be purified by alcohol previous to its being used medicinally. Storax has been recorded in the Pharmacopoeia of China and the United States Pharmacopoeia 43.

3. Historical and Traditional Use

3.1 Ancient Mediterranean and Classical World

Mnesimachus, Aristotle, Theophrastus (Historia Plantarum), Herodotus, and Strabo all mention the storax tree and its balsam. This species originated in the southern regions of Mesopotamia, present-day Iraq, and in particular Babylon, where Babylonians used it for respiratory-related diseases.

Pliny (Historia Naturalis 12.98, 15.26; 24.24) notes the use of storax as a perfume, while Scribonius Largus drank wine flavored with storax. Dioscorides (De materia medica 1.79) reports its use as incense, similar to frankincense, ascribing to it expectorant and soothing properties. Multiple rites call for storax in the Graeco-Egyptian Greek Magical Papyri.

In history, the essential oil of Styrax liquidus was reportedly known as Egyptian Queen Cleopatra's "love elixir" and used as a perfume oil. It has been used as a medicine since the time of Hippocrates. Ancient Egyptians used this oil during mummification. Amphoras filled with balsam extracted from sunken Phoenician ships indicated that Styrax liquidus had an important place in Mediterranean trade in antiquity.

3.2 Medieval Islamic and Chinese Traditions

Al-Masudi listed storax gum (mayʿa) as a spice in his book Murūdj al-dhahab (Meadows of Gold), published in the 10th century, and Chao Ju-Kuan, a trade commissioner in Fukien province, said in the 13th century that liquid storax gum had come from the Arabs.

During the Qin and Han dynasties, storax was introduced to China by the Silk Road and was widely used in healthcare and social life. In TCM, storax is classified as pungent and warm in nature, acting on the Heart and Spleen meridians. Its therapeutic effects include the ability to open the orifices and clear the mind, and to stop pain. Classical indications include sudden coma caused by qi stagnation or unconsciousness due to windstroke; storax was used with Musk, Cloves, and Benzoin in the formula Suhexiang Wan.

3.3 Turkish and Mediterranean Folk Medicine

L. orientalis is a plant known to have medicinal and cosmetic properties and is widely used in phytotherapy in the Mediterranean region. Styrax has been used for treatment of various ailments in Turkish folk medicine such as skin problems, peptic ulcers, nocturnal enuresis, parasitic infections, as an antiseptic or as an expectorant. The Styrax liquidus has been used for the treatment of various ailments in Turkish folk medicine. It is used to treat wounds, asthma, bronchitis, upper respiratory tract diseases, skin diseases like scabies, and it is used as an expectorant and antifungal.

3.4 Western Herbal and Pharmacopoeial History

Storax has been recommended as a remedy in diphtheria, in pulmonic catarrhs, and as a substitute for South American copaiba in gonorrhoea and leucorrhoea. Combined with tallow or lard, it has been described as valuable for many forms of skin disease, such as ringworm, especially in children.

The antituberculosis effect of cinnamic acid may explain the traditional use of storax (L. orientalis) and cinnamon for treating tuberculosis in the 19th century. Storax was once used in the United States as a component of hemorrhoid preparations, but more recently has been used as an ingredient in compound benzoin tincture for use as a topical protectant. Storax is used in food products as a flavoring and fixative, as well as in soaps and perfumes.

In North Africa, for ritual and mystical purposes, women burn benzoin and storax in potsherds.

Storax has been not only widely used as a folk medicine in East Asia, India, Africa, and Turkey for many years, but is also a popular spice for food and wine.

4. Key Phytochemical Constituents and Proposed Mechanisms of Action

4.1 Cinnamic Acid and Its Esters

The cinnamic acid fraction — encompassing free cinnamic acid, cinnamyl cinnamate (styracin), phenylpropyl cinnamate, ethyl cinnamate, and benzyl cinnamate — is considered central to many of storax's documented biological activities. Natural cinnamic acids from storax have demonstrated in vitro antimicrobial activity against a variety of human pathogens, including multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). The antituberculosis activity historically attributed to storax is linked to the cinnamic acid content.

4.2 Terpenoid Compounds

Pentacyclic triterpenes — including oleanolic acid, betulinic acid, corosolic acid, and maslinic acid — identified in storax are associated in preclinical models with anti-inflammatory, anticancer, and hepatoprotective activities. Monoterpenes such as terpinen-4-ol and α-terpinol in the essential oil fraction contribute to its antimicrobial and antifungal character.

4.3 Storesin

Storesin, the alcoholic resin fraction comprising 33–50% of purified storax, contributes to the balsam's fixative and antiseptic character, though it has been less studied in isolation compared to the aromatic acid fraction.

4.4 Mechanistic Pathways Identified in Preclinical Research

A 2021 systematic review published in Frontiers in Pharmacology (Xu et al.) summarized the mechanistic landscape for cardiovascular and cerebrovascular applications. The review showed that storax has pharmacological effects of anti-cerebral ischemia, regulation of the blood-brain barrier, bidirectional regulation of the central nervous system, anti-myocardial ischemia, anti-arrhythmia, anti-thrombosis, and anti-platelet aggregation. It mainly exerts its protective effects on the brain and heart through mechanisms such as inhibition of inflammatory immune factors, anti-oxidative stress, anti-apoptosis, pro-neovascularization, and regulation of NO release.

For cardiovascular fibrosis, storax has been shown to act through the renin–angiotensin system. Activation of the renin–angiotensin–aldosterone system (RAAS), which triggers apoptosis, is a major pathogenic mechanism involved in myocardial fibrosis; inhibition of the RAAS pathway — such as blocking the Ang II type 1 receptor (AT1R) — has proven to be an effective strategy for the clinical treatment of myocardial fibrosis. Storax is hypothesized to suppress the AT1R–Ankrd1–P53 signaling axis in cardiomyocytes.

For antimicrobial effects, the storax produced by injuring L. orientalis has good antiseptic properties. Biofilm disruption has also been characterized. Storax inhibits biofilm formation and reduces the preformed biofilm of microbial strains including Staphylococcus aureus (ATCC 33862), Pseudomonas aeruginosa (ATCC 27853), and Candida albicans (ATCC 64548). The results suggest that storax has strong cytotoxic, apoptotic, and antibiofilm properties.

For anticancer activity, a study on A549 lung cancer cells found that storax induces apoptosis via upregulating CASP3, 8, 9, and Bax gene expression and downregulating Bcl-2 expressions in A549 cells. Furthermore, storax decreases the expression of miR-146a, miR-21, and miR-223, while increasing the expression of miR-155.

For antioxidant activity, the gum demonstrated antioxidant capabilities in several assays, including in DPPH, ABTS, CUPRAC, and FRAP methods.

5. Scientific Evidence by Area of Use

Important general caveat: Although Liquidambar orientalis, known for its resinous exudate storax, has a widespread and well-established ethnopharmacological use, the number of existing scientific studies is very limited. The vast majority of evidence is preclinical — derived from in vitro cell studies or animal models — and no high-quality randomized controlled clinical trials in human populations have been identified in the peer-reviewed literature for any specific therapeutic indication.

5.1 Cardiovascular System: Myocardial Ischemia and Cardiac Fibrosis

Evidence level: Animal/preclinical only.

A 2022 study published in the International Journal of Molecular Sciences (Xu et al.) investigated storax's effects on cardiac fibrosis. This study explored the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The acute myocardial infarction (AMI) rat model was established by subcutaneous injection of isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once per day for 7 days. The study indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R–Ankrd1–P53 signaling pathway. This evidence is limited to a rodent model and has not been replicated in human clinical trials.

A 2024 study published in PLOS ONE (Huang et al.) examined both antithrombotic activity and myocardial infarction protection of styrax. Storax has been used in traditional Chinese medicine for its various pharmacological effects, including increasing coronary flow, improving microcirculation, lowering blood lipids and raising high-density lipoprotein, regulation of blood-brain barrier, anti-myocardial ischemia, anti-arrhythmia, anti-thrombosis, and anti-platelet aggregation. Again, these findings are drawn from preclinical work.

Chinese medicine compounds containing storax are widely used in Asian countries for the prevention and treatment of cardio-cerebrovascular diseases, primarily within compound formulas such as Guanxin Suhe Pill, in which storax is one ingredient among many. These compound preparations have been studied in clinical settings in China, but isolating the specific contribution of storax from these multi-ingredient formulas is methodologically difficult.

5.2 Cerebrovascular System: Ischemic Stroke and Blood-Brain Barrier

Evidence level: Animal/preclinical only.

A study published in Frontiers in Pharmacology / PMC (2022) examined storax's effect on the blood-brain barrier following ischemic stroke in rats. This study aimed to test the hypothesis that storax inhibits caveolae-mediated transcytosis at the blood-brain barrier (BBB) after ischemic stroke in rats. Male Wistar rats (250–300 g) were subjected to transient middle cerebral artery occlusion (t-MCAO). Storax treatment of 0.1 g/kg had no significant effects on brain lesions. Storax treatment of 0.2, 0.4, and 0.8 g/kg led to a significant decrease in infarction size, and the 0.4 and 0.8 g/kg groups displayed a significant reduction in brain water content. Storax treatment of 0.8 g/kg showed mild toxic reactions. Thus, 0.4 g/kg storax was selected as the optimal dose for subsequent studies.

Studies have shown that storax has the functions of inhibiting inflammatory responses and neuronal apoptosis, as well as protecting the integrity of the BBB. Blood-brain barrier disruption following ischemic stroke contributes to hemorrhagic transformation, brain edema, increased neural dysfunction, secondary injury, and mortality. The prevailing view attributes the destruction of tight junction proteins (TJs) to the resulting BBB damage following ischemic stroke. No human clinical trials in stroke patients using storax as a direct intervention have been identified.

5.3 Antimicrobial Activity

Evidence level: In vitro only.

Storax displayed bactericidal actions against various gram-positive bacteria, such as Staphylococcus aureus, and gram-negative strains, including Escherichia coli. Several researchers have reported that storax also has protective activity against many bacteria species, phytopathogenic fungi, and nematodes.

The synergy between L. styraciflua plant extracts and ciprofloxacin and tetracycline was studied using the checkerboard assay method against 8 bacterial strains. The study concluded that L. styraciflua demonstrates potentially synergistic interactions with antibiotics against bacteria. All antimicrobial research identified is in vitro, and no human clinical trials on storax for infectious disease have been reported.

5.4 Antioxidant Activity

Evidence level: In vitro only.

The antioxidant capacity of storax has been evaluated across multiple in vitro assay systems — DPPH, ABTS, CUPRAC, and FRAP. These standard chemical assays demonstrate radical-scavenging potential but do not establish in vivo or clinical efficacy. The phenolic acids (especially p-coumaric acid) and the aromatic resin fraction are considered the principal contributors to antioxidant activity in these assays. No human interventional studies on storax's antioxidant effects have been identified.

5.5 Anticancer Activity

Evidence level: In vitro only; preliminary.

Studies examining storax's anticancer potential have focused on in vitro cell line models. The aims of one published study were to determine the antibiofilm activity of storax and its cytotoxic and apoptotic effects in A549 lung cancer cells, including the effect of storax on certain microRNA expressions. The results suggest that storax has strong cytotoxic, apoptotic, and antibiofilm properties, and thus promising potential in medicine.

A study examined autophagy induction in prostate cancer cells and found that L. orientalis gum extract induces autophagy via the PI3K/Akt/mTOR signaling pathway. These results are preliminary cell-line findings; no clinical or animal model data on storax's anticancer effects in living organisms were identified in the peer-reviewed sources retrieved. Although it is known that storax has anticancer, antimicrobial, antioxidant, wound-healing, and other ethnomedicinal properties, the number of existing scientific studies is very limited.

5.6 Respiratory System

Evidence level: Traditional use; no clinical trials identified.

Storax is used as a topical parasiticide, expectorant, and for the treatment of some skin diseases in Turkish folk medicine. Its traditional use as an expectorant for respiratory ailments — including coughs, bronchitis, and upper respiratory tract diseases — is consistently reported across multiple traditional systems (Babylonian, Greek, Turkish, Chinese). Storax balsam has been employed in traditional medicine across various cultures primarily as an expectorant for respiratory ailments such as coughs and colds, often incorporated into compounds like Friar's Balsam. No controlled clinical trials in respiratory patients have been identified in the peer-reviewed literature.

5.7 Dermatological Applications

Evidence level: Traditional use; limited in vitro and one small observational study.

Topical application for skin diseases — including scabies, ringworm, wounds, and acne — is among the oldest recorded uses. Styrax is used externally as an antiseptic and parasiticide for skin disorders such as scabies and fungal illnesses. Storax oil has many therapeutic properties, including antioxidant, anti-inflammatory, antimicrobial, antifungal, anticancer, and anti-malarial due to its phenolic content. Styrax incorporated cryogels have been proposed as candidate biomaterials for tissue engineering applications, in particular for antimicrobial systems due to their ferrous ion chelating activity and high antioxidant, anti-biofilm, and antimicrobial properties. No controlled human trials on storax for dermatological conditions have been identified.

5.8 Gastrointestinal Applications

Evidence level: Traditional use only.

People use storax for stomach pain, eczema, common cold, cough, diarrhea, epilepsy, wound healing, and many other conditions, but there is no good scientific evidence to support these uses. Use for peptic ulcers is documented in Turkish folk medicine, and one study investigated characterization of volatile components alongside an anti-ulcerogenic effect, but clinical evidence remains absent.

6. Body Systems and Health Areas of Association

• Cardiovascular: Anti-myocardial ischemia, anti-arrhythmia, anti-thrombosis, anti-platelet aggregation, anti-cardiac fibrosis, increased coronary flow — studied in animal models.
• Cerebrovascular / Neurological: Anti-cerebral ischemia, regulation of the blood-brain barrier, bidirectional regulation of the central nervous system — studied in rodent stroke models.
• Respiratory: Expectorant, bronchodilatory, and anti-asthmatic actions — based on traditional use and theoretical mechanisms; no clinical data.
• Dermatological: Antiseptic, wound-healing, antiparasitic, antifungal — traditional use and in vitro data.
• Antimicrobial / Anti-infective: Bactericidal against gram-positive and gram-negative pathogens; antibiofilm — in vitro data only.
• Oncological: Cytotoxicity, apoptosis induction, autophagy induction in cancer cell lines — in vitro preclinical only.
• Gastrointestinal: Anti-ulcer, antidiarrheal — traditional use only.
• Cosmetic / Fragrance: Fixative, aromatic base, flavoring — established commercial use.

7. Dosage Forms and Reported Dosages

No standardized human therapeutic dosage has been established in the peer-reviewed clinical literature. Dosages reported in animal studies are as follows:

• Cardiac fibrosis (rat model, gavage): Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once per day for 7 days.
• Ischemic stroke / BBB protection (rat model, t-MCAO): Storax treatment of 0.1 g/kg had no significant effects on brain lesions. Storax treatment of 0.2, 0.4, and 0.8 g/kg led to a significant decrease in infarction size. Storax treatment of 0.8 g/kg showed mild toxic reactions. Thus, 0.4 g/kg storax was selected as the optimal dose for subsequent studies.

In terms of forms, storax has been used as a folk medicine in East Asia, India, Africa, and Turkey in topical, inhalant, and orally ingested forms. Storax is used in food products as a flavoring and fixative, as well as in soaps and perfumes, representing commercial applications where small quantities are incorporated as flavoring agents or fragrance materials rather than as therapeutic doses.

8. Safety Considerations

8.1 General Safety and Regulatory Status

When taken by mouth: storax is commonly consumed in foods. It is possibly safe when used in appropriate amounts as medicine. Storax is GRAS (Generally Recognized as Safe) for use as a flavoring agent in foods, including chewing gum, in accordance with good manufacturing practices under 21 CFR Parts 182 and 184.

8.2 Skin Sensitization and Contact Dermatitis

Storax balsam can cause acute skin irritation and contact dermatitis upon topical application, primarily due to its cinnamate components, with symptoms including rash and redness reported in sensitive individuals. Chronic exposure raises concerns for allergic sensitization, though incidence remains rare at less than 1% in general populations, often linked to cross-reactivity with related balsams like Peru balsam.

In the European Union, storax balsam extracts and oils are regulated under the Cosmetics Regulation (EC) No 1223/2009, with provisions in Annex III restricting certain fragrance allergens derived from cinnamyl compounds, such as cinnamyl alcohol, to a maximum concentration of 0.001% in leave-on products to mitigate sensitization risks.

8.3 Genotoxicity and Cytotoxicity Concerns

A published in vitro study (Karadeniz et al., Toxicology and Industrial Health, 2013) specifically examined genotoxic potential. The study investigated the effects of storax balsam on cell viability, cytotoxicity, and genotoxicity in human lymphocytes in vitro. The genotoxic effects of the extract of storax balsam (SE) were studied using the sister chromatid exchange (SCE) test system. The cytotoxic and inhibitory effects on cell proliferation of SE were evaluated using LDH assay and WST-1 assay. The SCE frequency was increased when the cells were treated with 1.6 and 4.0 µg/mL SE concentrations (p < 0.05). Moreover, treatment of the cells with the same concentrations significantly depleted cell number at 24th and 48th hours and elevated LDH levels (p < 0.05) at 48th hour.

In spite of frequent use of styrax in Turkish folk medicine as well as its prior use as a stabilizer in the perfumery industry, negative reports have been noticed by international authorities for restriction of its use based on some limited evidence from in vitro studies. A subsequent study aimed to evaluate the genotoxic and cytotoxic potential of styrax and its ethanolic extract using in vivo and in vitro assays, as well as an antimutagenic assay. Regulatory health risk assessment is considered mandatory for the safe use of such herbal materials not only in the case of sensitization but also with special concerns regarding genotoxicity potential.

It should be noted that genotoxic and cytotoxic signals observed in in vitro lymphocyte assays do not automatically translate to in vivo harm at relevant exposures, but they do indicate a need for caution and further regulatory evaluation, particularly for internal therapeutic use.

8.4 Styrene Content and IARC Classification

Potential carcinogenicity is unproven for storax balsam itself, but trace amounts of styrene — a known component — warrant caution, as styrene is classified by the International Agency for Research on Cancer (IARC) as a possible human carcinogen.

8.5 Inhalation Risk

Inhalation of undiluted storax balsam vapors can result in respiratory irritation, manifesting as coughing, wheezing, shortness of breath, or burning sensations in the airways.

8.6 Gastrointestinal Effects

Gastrointestinal upset, such as diarrhea, may occur with oral ingestion of large amounts exceeding moderate doses, potentially leading to more severe effects if consumed excessively.

8.7 Animal Study Toxicity Signal

In the rat t-MCAO model, storax treatment of 0.8 g/kg showed mild toxic reactions, leading investigators to select 0.4 g/kg as the upper working dose in subsequent experiments. This signals a potential dose-dependent toxicity window, at least in rodents.

8.8 Adulteration

Storax is sometimes adulterated with mineral matters, resin, turpentine, etc. If large quantities of resins are present, the balsam hardens in cold weather; genuine storax has at all seasons more or less the consistency of honey. Adulteration is a practical quality-control concern for both consumer and researcher.

9. Overall Evidence Assessment

Storax is a resin with a multimillennial history of therapeutic application across Mediterranean, Middle Eastern, Central Asian, and East Asian traditions, with especially deep roots in Traditional Chinese Medicine. Its phytochemistry is well characterized — dominated by cinnamic acid esters, storesin, and a diverse terpenoid fraction — and multiple biological mechanisms have been elucidated at the preclinical level, particularly in cardiovascular and cerebrovascular animal models.

However, the overall scientific evidence base for clinical therapeutic efficacy in humans remains weak. The research identified consists almost entirely of in vitro cell-line experiments and rodent model studies. Clinical trials in humans are sparse, and the efficacy of storax balsam in nutritional products has not been decisively established. While early findings are encouraging and support its traditional uses, more rigorous scientific investigations are needed to validate its health benefits and determine optimal dosages.

The most scientifically substantiated areas of research — cardiac fibrosis and blood-brain barrier protection — remain at the animal study stage. Its use in compound TCM preparations (Guanxin Suhe Pill, etc.) in East Asian clinical practice represents traditional medicine integration that does not constitute controlled evidence for storax's individual contribution. Safety considerations — particularly genotoxicity signals in vitro and styrene content — require further regulatory and toxicological resolution before therapeutic dosing recommendations can be made with confidence.

References

• Evaluation of the Potential Therapeutic Properties of Liquidambar orientalis Oil — PubMed (2023)
• The Antimicrobial Activity of Liquidambar orientalis Mill. Against Food Pathogens and Antioxidant Capacity of Leaf Extracts — PMC (2014)
• Storax balsam — Wikipedia
• Biological Activities and Chemical Composition of Turkish Sweetgum Balsam (Styrax Liquidus) Essential Oil — Bezmialem Science
• Storax Uses, Benefits & Dosage — Drugs.com (Natural Product Monograph)
• Storax, A Promising Botanical Medicine for Treating Cardio-Cerebrovascular Diseases: A Review — Frontiers in Pharmacology / PMC (2021)
• Storax Inhibits Caveolae-Mediated Transcytosis at Blood-Brain Barrier After Ischemic Stroke in Rats — PMC (2022)
• Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway — International Journal of Molecular Sciences (2022)
• Effects of grafting on chemical constituents, toxicological properties, antithrombotic activity, and myocardial infarction protection of styrax secreted from Liquidambar orientalis Mill — PLOS ONE / PMC (2024)
• Genotoxic and cytotoxic effects of storax in vitro — Toxicology and Industrial Health (2013)
• Safety evaluation of styrax liquidus from the viewpoint of genotoxicity and mutagenicity — Journal of Ethnopharmacology (2016)
• Biological activities of Liquidambar orientalis: Antibiofilm, cytotoxicity, apoptosis, and miRNA expressions — ResearchGate (2024)
• Chemical Evaluation of Liquidambar styraciflua L. Fruits Extracts and Their Potential as Anticancer Drugs — PMC (2023)
• Storax: Overview, Uses, Side Effects, Precautions, Interactions — WebMD Vitamins & Supplements
• A Modern Herbal | Storax — Botanical.com (Grieve)
• Storax, A Promising Botanical Medicine for Treating Cardio-Cerebrovascular Diseases: A Review — Frontiers in Pharmacology (2021)
• Properties and usage of Liquidambar orientalis — OA Text (2018)